The Presentation of Additional BETonMACE Results to Supplement AHA Late Breaking Science Session held on November 16, 2019

CALGARY, Alberta, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announces that it has scheduled a conference call and webcast to supplement the presentation of BETonMACE results to be made during the American Heart Association’s (“AHA”) annual conference. As previously reported, the primary results of the BETonMACE trial will be presented on November 16th during the AHA’s Scientific Sessions 2019 held in Philadelphia, Pennsylvania; additional details can be found HERE. Following the AHA presentation, the Company will host a conference call and webcast currently scheduled for 8:30 am ET on November 18th, 2019.

For those wishing to join the November 18th event, it is highly recommended to access the webcast over the Internet using the following LINK. A replay of the webcast (using the same link provided) will be available for one month following the conclusion of the event.

If dialing in by phone, dial 1-800-319-4610 (within Canada / USA) or +1-604-638-5340 (International Toll). Callers should dial-in at least 10 min prior to the scheduled start time. A teleconference replay will be available for two weeks following the conclusion of the event and can be accessed by dialing 1-800-319-6413 (within Canada / USA) or +1-604-638-9010 (International Toll) and using the replay access code: 3856#.

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RV